Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q3 2022 call → NOThe question asks whether management repeatedly redirects attention away from the conventional yardstick and toward a different part of the business that is already earning, while indicating the record hasn't caught up. Let me analyze the transcript. The company is Cue Biopharma, a biotech developing immunotherapies. The call discusses CUE-101 (monotherapy and combination with pembrolizumab) and CUE-102. The conventional yardstick for a biotech in clinical trials would be... well, what would it be? For a clinical-stage biotech, the conventional measure might be clinical trial results, efficacy data, or perhaps revenue. But this company has minimal revenue ($68,000 in collaboration revenue). The call is entirely about clinical data. Let me look for any redirection. The call discusses: - CUE-101 monotherapy data - CUE-101 + pembrolizumab combination data - CUE-102 (WT1 targeting) trial - Financial update Is there any point where management says "the thing you usually watch is no longer the right thing to watch"? I don't see that. The call is a standard clinical update call. Management presents clinical data, discusses survival, response rates, etc. The question's framework seems designed for companies where there's a shift from one business metric to another (e.g., from commodity price to processing business, from equipment sales to services). Here, the company is a clinical-stage biotech. The "conventional yardstick" might be... revenue? But the company has essentially no revenue. Or perhaps the conventional yardstick is the monotherapy data vs. the combination data? Actually, let me re-read. The call discusses both monotherapy and combination. There's no sense that management is setting aside one measure and pointing to another that is "already earning." The company has no products earning revenue. Everything is clinical-stage. The question asks: does management point to a different part of the business that is "ALREADY EARNING" - actual revenue, orders, customers, etc.? No. The company's only revenue is $68,000 in collaboration revenue. The clinical programs are all investigational. Management does not set aside any conventional yardstick. The call is a standard earnings/clinical update. There's no redirection to a different part of the business that is already earning. Therefore, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.